Dynavax (DVAX) Tops Q3 EPS by 5c

Go back to Dynavax (DVAX) Tops Q3 EPS by 5c

Dynavax Reports Fourth Quarter and Year End 2015 Financial Results

March 8, 2016 7:00 AM EST

BERKELEY, CA -- (Marketwired) -- 03/08/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2015.

The Company had $196.1 million in cash, cash equivalents and marketable securities as of December 31, 2015.

Total revenues for the year ended December 31, 2015, decreased by $7.0 million or 63 percent compared to the same period in 2014, primarily due to a $5.2 million decrease in collaboration revenue due to winding down of work performed for the AZD1419 program and expiration of our collaboration agreement with GSK in 2014.

Operating expenses increased by $6.8 million or seven percent... More